PXD047873

PXD047873 is an original dataset announced via ProteomeXchange.

Title	A CTL-inspired Killing System Reveals Ultralow-dose Chemotherapy is Sufficient for Inducing a Pyroptosis-mediated Antitumour Immune Function
Description	A Cytotoxic T lymphocyte-inspired system capable of using ultralow-dose chemical drugs to manipulate cell death is needed to investigate the antitumour immunotherapy. Recent studies revealed pyroptosis, a proinflammatory type of cell death, could promote antitumour immune function. However, high-dose chemotherapy led to cytokine release syndrome by pyroptosis. Therefore, pyroptosis- inducing ultralow-dose chemotherapy was potential in preclinical and clinical research, but its efficacy, safety and the antitumour immune responses were not clear. Here, we established a near-infrared light controllable killing system (BIK system) by which ultralow-dose doxorubicin could be spatiotemporally transported to immunosuppressive tumour cells and mediate efficient pyroptosis. Compared with using DOX directly, the BIK system reduced total drug consumption to less than one- thirtieth the common dose in vitro. MPI imaging and fluorescence imaging showed our BIK system exhibited good tumour targeting and tumour penetration. We applied this system for pyroptosis-induced antitumor therapies, and the results showed that less than 43 µg kg-1 DOX was sufficient for GSDME-positive tumour regression with negligible injuries to major organs. Notably, the gasdermin-deficient 4T1 tumours could be controlled by combining BIK system with decitabine treatment. The antitumour immune function were proven to correlate with the impressive efficacy of pyroptosis-inducing ultralow-dose chemotherapy, and the concomitant immune memory prevented metastasis, but high-dose DOX led to poor T cells infiltration which caused immunosuppression and lung metastasis. Owing to the robust antitumour immune function induced by BIK system, advanced-stage bulky tumours could be controlled or shrunken by synergizing with anti-PD-1 therapy. This study provided new insights into the design of nanoassisted systems for activating the antitumour immune function by microstimulation; our application of the BIK system suggested that ultralow-dose chemotherapy was sufficient for inducing a robust pyroptosis-mediated antitumour immune function
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_06:31:29.757.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	hao yin
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: 10090;
ModificationList	No PTMs are included in the dataset
Instrument	6410 Triple Quadrupole LC/MS

Revision	Datetime	Status	ChangeLog Entry
0	2023-12-17 03:34:25	ID requested
1	2024-02-22 21:46:38	announced
⏵ 2	2024-10-22 06:31:30	announced	2024-10-22: Updated project metadata.

10.1002/ADMA.202309839;

submitter keyword: Mouse, Antitumor Immune, Pyroptosis

hao yin
contact affiliation	Institute for Advanced Research, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
contact email	yinhao@wmu.edu.cn
lab head
hao yin
contact affiliation	Institute for Advanced Research, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
contact email	yinhao@wmu.edu.cn
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/02/PXD047873

PRIDE project URI

• PRIDE
  1. PXD047873
     1. Label: PRIDE project
     2. Name: A CTL-inspired Killing System Reveals Ultralow-dose Chemotherapy is Sufficient for Inducing a Pyroptosis-mediated Antitumour Immune Function